Literature DB >> 28831601

Endothelin-1, α-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients.

Mehrzad Hajialilo1, Parisa Noorabadi1, Sepideh Tahsini Tekantapeh1, Aida Malek Mahdavi2.   

Abstract

Considering the role of endothelin-1 (ET-1) in tissue remodeling and fibrosis during the development of scleroderma as well as the effect of α-Klotho in pathogenesis of calcinosis and/or endothelial cell injury and its correlation with severity of disease, this study aimed to evaluate serum ET-1, α-Klotho and 25(OH) vitamin D levels in patients with limited and diffuse scleroderma compared to healthy subjects. In this cross-sectional study, 60 scleroderma patients according to the ACR/EULAR 2013 criteria and 60 age- and sex-matched healthy controls were included. In patients, clinical examination was performed and Medsger severity scale was assessed. Serum ET-1, soluble α-Klotho and 25(OH)D3 levels were measured using ELISA kits. The mean ± SD age of patients and controls was 46.2 ± 9.6 and 47.2 ± 7.0 years, respectively. Compared to healthy controls, serum ET-1 was significantly higher in SSc patients (p = 0.001); whilst serum α-Klotho and 25(OH)D3 were significantly lower in patients (p = 0.001). The most common organs involved in patients were skin, lung, peripheral vascular and gastrointestinal system and the severity of involvement was mainly mild and/or moderate. There were no significant differences in serum ET-1 and α-Klotho levels according to the severity of different organ involvement (p > 0.05). There was no significant correlation between presence or absence of calcinosis and negative or positivity of auto-antibodies with ET-1, α-Klotho and 25(OH)D3 levels. Although our study revealed higher serum ET-1 and lower serum α-Klotho levels in SSc patients compared to healthy controls, there were not any significant correlations between their serum levels with severity of organ involvement.

Entities:  

Keywords:  Endothelin-1; Systemic sclerosis; α-Klotho

Mesh:

Substances:

Year:  2017        PMID: 28831601     DOI: 10.1007/s00296-017-3797-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  58 in total

1.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

2.  Clinical significance of serum levels of sCD36 in patients with systemic sclerosis: preliminary data.

Authors:  Iman H Bassyouni; Tamer A Gheita; Roba M Talaat
Journal:  Rheumatology (Oxford)       Date:  2011-09-02       Impact factor: 7.580

Review 3.  Implications of Klotho in vascular health and disease.

Authors:  Ernesto Martín-Núñez; Javier Donate-Correa; Mercedes Muros-de-Fuentes; Carmen Mora-Fernández; Juan F Navarro-González
Journal:  World J Cardiol       Date:  2014-12-26

Review 4.  Systemic sclerosis.

Authors:  Gabriele Valentini; Carol Black
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-12       Impact factor: 4.098

5.  Severely reduced production of klotho in human chronic renal failure kidney.

Authors:  N Koh; T Fujimori; S Nishiguchi; A Tamori; S Shiomi; T Nakatani; K Sugimura; T Kishimoto; S Kinoshita; T Kuroki; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  2001-02-02       Impact factor: 3.575

6.  Circulating α-klotho levels in CKD and relationship to progression.

Authors:  Hyoung Rae Kim; Bo Young Nam; Dong Wook Kim; Min Woong Kang; Jae-Hyun Han; Mi Jung Lee; Dong Ho Shin; Fa Mee Doh; Hyang Mo Koo; Kwang Il Ko; Chan Ho Kim; Hyung Jung Oh; Tae-Hyun Yoo; Shin-Wook Kang; Dae Suk Han; Seung Hyeok Han
Journal:  Am J Kidney Dis       Date:  2013-03-27       Impact factor: 8.860

7.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.

Authors:  D J Abraham; R Vancheeswaran; M R Dashwood; V S Rajkumar; P Pantelides; S W Xu; R M du Bois; C M Black
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

8.  Klotho suppresses RIG-I-mediated senescence-associated inflammation.

Authors:  Feng Liu; Su Wu; Hongwei Ren; Jun Gu
Journal:  Nat Cell Biol       Date:  2011-02-20       Impact factor: 28.824

Review 9.  Vascular disease in scleroderma: angiogenesis and vascular repair.

Authors:  Mary Jo Mulligan-Kehoe; Michael Simons
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

10.  Endothelin-1 levels in scleroderma patients: a pilot study.

Authors:  Emanuele Cozzani; Sanja Javor; Erika Laborai; Massimo Drosera; Aurora Parodi
Journal:  ISRN Dermatol       Date:  2013-07-30
View more
  10 in total

Review 1.  The Nax (SCN7A) channel: an atypical regulator of tissue homeostasis and disease.

Authors:  David Dolivo; Adrian Rodrigues; Lauren Sun; Yingxing Li; Chun Hou; Robert Galiano; Seok Jong Hong; Thomas Mustoe
Journal:  Cell Mol Life Sci       Date:  2021-06-08       Impact factor: 9.261

Review 2.  The role of endothelin and RAS/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications.

Authors:  Mohsen Rokni; Mina Sadeghi Shaker; Hoda Kavosi; Shahrzad Shokoofi; Mahdi Mahmoudi; Elham Farhadi
Journal:  Arthritis Res Ther       Date:  2022-05-13       Impact factor: 5.606

Review 3.  Sirtuins and Accelerated Aging in Scleroderma.

Authors:  Anne E Wyman; Sergei P Atamas
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

4.  Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans.

Authors:  Yi Zhu; Larissa G P Langhi Prata; Erin O Wissler Gerdes; Jair Machado Espindola Netto; Tamar Pirtskhalava; Nino Giorgadze; Utkarsh Tripathi; Christina L Inman; Kurt O Johnson; Ailing Xue; Allyson K Palmer; Tingjun Chen; Kalli Schaefer; Jamie N Justice; Anoop M Nambiar; Nicolas Musi; Stephen B Kritchevsky; Jun Chen; Sundeep Khosla; Diana Jurk; Marissa J Schafer; Tamar Tchkonia; James L Kirkland
Journal:  EBioMedicine       Date:  2022-03-13       Impact factor: 11.205

Review 5.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

Authors:  Olivier Bonhomme; Béatrice André; Fanny Gester; Dominique de Seny; Catherine Moermans; Ingrid Struman; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

6.  Role of Vitamin D in Systemic Sclerosis: A Systematic Literature Review.

Authors:  Alexandra-Diana Diaconu; Iustina Ostafie; Alexandr Ceasovschih; Victorița Șorodoc; Cătălina Lionte; Codrina Ancuța; Laurențiu Șorodoc
Journal:  J Immunol Res       Date:  2021-11-29       Impact factor: 4.818

Review 7.  Vitamin D in Systemic Sclerosis: A Review.

Authors:  Mattia Perazzi; Enrico Gallina; Giulia Francesca Manfredi; Filippo Patrucco; Antonio Acquaviva; Donato Colangelo; Mario Pirisi; Mattia Bellan
Journal:  Nutrients       Date:  2022-09-21       Impact factor: 6.706

8.  Dualities of the vitamin D in systemic sclerosis: a systematic literature review.

Authors:  Laiana Schneider; Vanessa Hax; Odirlei Monticielo; Tamires Ferri Macedo; Roberta Kern Menna Barreto; Natália Aydos Marcondes; Rafael Chakr
Journal:  Adv Rheumatol       Date:  2021-06-09

9.  Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release.

Authors:  Audrey Benyamine; Jérémy Magalon; Florence Sabatier; Luc Lyonnet; Stéphane Robert; Chloé Dumoulin; Sophie Morange; Karin Mazodier; Gilles Kaplanski; Martine Reynaud-Gaubert; Pascal Rossi; Françoise Dignat-George; Brigitte Granel; Pascale Paul
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

10.  Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.

Authors:  Lukas Bankamp; Beate Preuß; Ann-Christin Pecher; Nicola Beucke; Jörg Henes; Reinhild Klein
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.